Outcomes15

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 15 of 15

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Score on a scale	MEAN
PRIMARY	Change in Body Weight	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of body weight	MEAN
SECONDARY	Change in Six-minute Walking Distance (6MWD)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Meters	MEAN
SECONDARY	The Hierarchical Composite Endpoint: Percentage of Wins of Participant Pairs	From baseline (week 0) to end of study (week 57)	FAS included all the randomized participants for this trial.	Percentages of wins of participant pairs	NUMBER
SECONDARY	Change in C-Reactive Protein (CRP): Ratio to Baseline	From baseline (week -2) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Ratio of C-reactive protein	GEOMETRIC_MEAN
SECONDARY	Percentage of Participants Achieving 10 Percent (%) Weight Loss (Yes/No)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of participants	NUMBER
SECONDARY	Percentage of Participants Achieving 15% Weight Loss (Yes/No)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of participants	NUMBER
SECONDARY	Percentage of Participants Achieving 20% Weight Loss (Yes/No)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of participants	NUMBER
SECONDARY	Percentage of Participants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of participants	NUMBER
SECONDARY	Percentage of Participants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of participants	NUMBER
SECONDARY	Change in KCCQ Overall Summary Score (KCCQ-OSS)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Score on a scale	MEAN
SECONDARY	Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in KCCQ-CSS (PGI-S)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of Participants	NUMBER
SECONDARY	Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participants Change in 6MWD (PGI-S)	From baseline (week 0) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Percentage of Participants	NUMBER
SECONDARY	Change in Systolic Blood Pressure (SBP)	From baseline (week -2) to end of treatment (week 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	millimetre of mercury (mmHg)	MEAN
SECONDARY	Change in Waist Circumference	From baseline (week 0) to end of treatment (visit 52)	FAS included all the randomized participants for this trial. Here, Overall Number of Participants Analyzed signifies those participants who had an observed value at week 52.	Centimeter	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04788511/outcomes

API reference For AI assistants